Abstract 5989
Background
IP CT after upfront cytoreductive surgery has been the standard of care in EOC. Nevertheless, results from the recent GOG252 trial showed no impact of this strategy vesus IV CT in the concurrence of bevacizumab therapy. The aim of this study was to perform a meta-analysis of the survival benefit of IP vs IV CT after cytoreductive surgery including recent evidence.
Methods
A literature search in order to identify most relevant RCT comparing IV vs IP CT after cytoreductive surgery in EOC was performed. Non comparative studies or trials with no hazard or risk ratios were excluded. Statistical analyses were done using SPSS STATISTICS V.21. Fixed-effect meta-analysis for combining data was made. Degree of heterogeneity using the I2statistic was calculated. Endpoints meta-analysed were disease-free survival (DFS) and overall survival (OS).
Results
Initially 92 papers were identified. After exclusion criteria only nine RCT including pooled data from 3668 pts (2068 treated with IP CT and 1620 treated with IV CT) were included. In 8 RCTs IPCT was given after upfront surgery and in 1 (OV21/PETROC) after neoadjuvant CT. In all RCTs 6 CT cycles were foreseen in the IP arms. Seven RCTs including 3006 pts had DFS as endpoint. Among these, GOG252 cohorts A and B were analysed separately. IP CT showed a survival benefit over IV CT with HR = 0.86; (95% confidence interval (CI): 0.80 to 0.93). Heterogeneity was moderate (I2=37.3) Eight RCTs including 2289 pts had OS as endpoint. IP CT showed a significant impact on OS with HR = 0.81; 95% CI: 0.73 to 0.90). Heterogeneity was low (I2<0.01). Benefit of IP CT remained unchanged in the sensitivity analysis performed for both DFS and OS by eliminating the latest RCT of the meta-analysis.
Conclusions
IP CT benefits DFS and OS in this meta-analysis of pooled data from 9 RCTs and 3668 pts including latest negative results.
Clinical trial identification
Legal entity responsible for the study
Hospital Clinico Universitario de Valencia. INCLIVA.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract